4 months ago
IFRX
AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Analyst Ranking
Top 11%
#597 out of 5502 analysts
Average Return
+75.21%
Win Rate
74%17 out of 23
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | +296.49% | $39.07 | $154.91 | 2025-08-06 - 2026-08-05 | Buy |
Inozyme Pharma IncINZY | +270.37% | $1.08 | $4.00 | 2025-03-12 - 2025-07-01 | Buy |
Liquidia CorpLQDA | +212.66% | $25.20 | $78.79 | 2025-08-13 - 2026-08-12 | Strong Buy |
Liquidia CorpLQDA | +183.15% | $9.79 | $27.72 | 2024-08-19 - 2025-08-18 | Strong Buy |
Liquidia CorpLQDA | +177.20% | $15.26 | $42.30 | 2025-05-09 - 2026-05-08 | Strong Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
9 months ago
PVLA
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Alpha Cognition IncACOG | 1 | Buy | $20.00 | +114.71% | Initiates Coverage On | 2 months ago |
Tvardi Therapeutics IncTVRD | 3 | Buy | $10.00 | +431.91% | Upgrades | 2 months ago |
Inflarx NvIFRX | 1 | Strong Buy | $9.00 | +293.01% | Upgrades | 4 months ago |
Apellis Pharmaceuticals IncAPLS | 3 | Hold | N/A | N/A | Downgrades | 5 months ago |
Palvella Therapeutics IncPVLA | 2 | Strong Buy | $143.00 | -6.51% | Upgrades | 9 months ago |
Liquidia CorpLQDA | 4 | Strong Buy | $41.00 | N/A | Maintains | a year ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $27.00 | N/A | Maintains | a year ago |
Ardelyx IncARDX | 2 | Buy | $12.00 | N/A | Maintains | a year ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $122.00 | N/A | Maintains | a year ago |
Inozyme Pharma IncINZY | 2 | Hold | $4.00 | N/A | Downgrades | a year ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | N/A | Maintains | 2 years ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.